MedPath

TO STUDY THE NATURE OF DISEASE(SYSTEMIC LUPUS ERYTHEMATOSUS)AND ALSO ROLE OF BIOCHEMICAL MARKER( SERUM ADENOSINE DEAMINASE LEVELS) IN RELATION TO SEVERITY OF DISEASE(SYSTEMIC LUPUS ERYTHEMATOSUS)

Not Applicable
Conditions
Health Condition 1: M329- Systemic lupus erythematosus, unspecified
Registration Number
CTRI/2020/09/028063
Lead Sponsor
TUKURU NITHIN KUMAR REDDY
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients diagnosed with systemic lupus erythematosus using SLICC

criteria.

Exclusion Criteria

Active TB and previously diagnosed with TB, and autoimmune diseases like rheumatoid arthritis, psoriasis, systemic sclerosis.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the association between serum adenosine deaminase levels and <br/ ><br>disease activity of systemic lupus erythematosus.Timepoint: OCTOBER 2021
Secondary Outcome Measures
NameTimeMethod
1.To study the clinical profile of systemic lupus erythematosus. <br/ ><br>2.To compare serum adenosine deaminase levels with other conventional markers like <br/ ><br>ESR, CRP, ESR/CRP RATIO, C3, C4, ANTI ds dna, and random urine protein creatinine <br/ ><br>ratio.Timepoint: OCTOBER 2021
© Copyright 2025. All Rights Reserved by MedPath